Updates at Diakonos Research Ltd.

Summer 2015: Diakonos Origination

Winter 2015: Diakonos Licenses Initial Intellectual Property From Baylor College of Medicine, Houston, Tx. (Link)

Spring 2016: Breakthrough Publication: The Diakonos-BCM lab publishes a groundbreaking paper regarding novel functionality of dendritic cells and the immune system. (Link)

Spring 2016: New Technology: Diakonos-BCM lab successfully develops a new technology regarding dendritic cell immuno-therapeutic functions and strengthens original IP while adding new and independent IP.

Spring 2016: Press Release: Baylor College of Medicine issues press release concerning the importance of the discovery (Link)

Spring 2016: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to portfolio.

Spring 2016: Breakthrough Publication: The Diakonos-BCM lab publishes a top-of-the-line proof-of-principle study displaying the power of Diakonos Immunotherapy in a hard-to-treat preclinical cancer model. (Link)

Summer 2017: Breakthrough Publication: The Diakonos-BCM lab publishes on a newly developed technology involving the use of dendritic cells and the treatment of Chagas (Link)

Fall 2017: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to portfolio.

Winter 2017: New Technology: Diakonos-BCM lab successfully develops a new technology regarding tumor antigenic preparations which further optimizes initial IP.

Spring 2018: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to portfolio.

Beginning 2018: Breakthrough Publication: The Diakonos-BCM lab publishes a top-of-the-line mechanistic study displaying the power of Diakonos Immunotherapy in a hard-to-treat models. (Link)

Spring 2018: External Licensing Deal: Diakonos and APAC Biotech agree to licensing deal re: APAC's use of patented Diakonos Tech (Link)

Spring 2018: First in human treatment with Diakonos Technology - First cancer patient (stage IV prostate; hospice) treated abroad with Diakonos cancer vaccine. As of Spring 2020, cancer free.

Summer 2018: Affiliated investigators receive FDA regulatory clearance for a Phase I clinical trial of resectable pancreatic cancer (PDAC).

Summer 2019: Affiliated investigators receive FDA regulatory clearance for a Phase I clinical trial of newly-diagnosed GBM

Summer 2019: Press Release: re: GBM trial and approvals (Link)

Summer 2019: 10th patient treated abroad in India. Observations thus far have included safety, metastatic cease, directed immune responses, shrinking tumors, and increased survival in multiple subjects with different cancers and stages.

Summer 2019: Breakthrough Publication: The Diakonos-BCM lab publishes results of canine splenic hemangiosarcoma trial in Diakonos vaccine was successfully employed. (Link)

Fall 2019: New Technology: Diakonos-BCM lab successfully develops a new technology regarding improved T-cell vehicles resulting from vaccine, which further protects initial IP as well as creates new IP.

Winter 2019: IP LicensureDiakonos successfully licenses this additional intellectual property and adds to portfolio.

Winter 2019: Affiliated investigators receive institutional IRB regulatory clearance for a Phase I clinical trial of resectable PDAC

Spring 2020: Breakthrough Publication: The Diakonos-BCM lab publishes groundbreaking research determining intricate mechanistic detail regarding vaccine function. (Link coming soon)

Spring 2020: Tentative External Licensing Deal ongoing: Diakonos and Cura agree to licensing deal re: use of patented Diakonos Tech in Cancun

Spring 2020: New Technology: Lab develops a wholly new technology in which tumors are treated with a one-of-a-kind cocktail of scientifically backed reagents which simultaneously weaken the tumor defense network and arm several important immunological arms.

Spring 2020: This unique cocktail (temporarily termed "TumorPrep") is being utilized in a canine breast cancer trial with encouraging preliminary results.

Diakonos Research Ltd.

1110 Nasa Parkway Suite 108i

Houston, TX 77058

©2016 BY DIAKONOS RESEARCH LTD.

832-746-3427